NOVARTIS generic arm Sandoz has signed an agreement with Pear Therapeutics to develop and commercialise prescription "digital therapeutics" for patients with substance use disorder and opioid use disorders.
The deal involves software called reSET, and has been approved by the US FDA - peartherapeutics.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Apr 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Apr 18
